-
1
-
-
38849091997
-
Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond
-
DOI 10.1002/sim.2929
-
M.J. Pencina R.B. D'Agostino Sr R.B. D'Agostino Jr R.S. Vasan 2008 Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 157 172 10.1002/sim.2929 17569110 (Pubitemid 351193639)
-
(2008)
Statistics in Medicine
, vol.27
, Issue.2
, pp. 157-172
-
-
Pencina, M.J.1
D'Agostino Sr., R.B.2
D'Agostino Jr., R.B.3
Vasan, R.S.4
-
2
-
-
49949092132
-
Role of secretory phospholipases in atherogenesis
-
10.1007/s11883-008-0039-6 18489854
-
A.C. Jönsson-Rylander S. Lundin B. Rosengren, et al. 2008 Role of secretory phospholipases in atherogenesis Curr Atheroscler Rep 10 252 259 10.1007/s11883-008-0039-6 18489854
-
(2008)
Curr Atheroscler Rep
, vol.10
, pp. 252-259
-
-
Jönsson-Rylander, A.C.1
Lundin, S.2
Rosengren, B.3
-
3
-
-
33847612773
-
Biomarkers of atherosclerotic plaque instability and rupture
-
DOI 10.1161/01.ATV.0000251503.35795.4f, PII 0004360520070100000005
-
W. Koenig N. Khuseyinova 2007 Biomarkers of atherosclerotic plaque instability and rupture Arterioscler Thromb Vasc Biol 27 15 26 10.1161/01.ATV.0000251503.35795.4f 1:CAS:528:DC%2BD28XhtlSrsb7I 17082488 (Pubitemid 46360377)
-
(2007)
Arteriosclerosis, Thrombosis, and Vascular Biology
, vol.27
, Issue.1
, pp. 15-26
-
-
Koenig, W.1
Khuseyinova, N.2
-
4
-
-
38749112555
-
Inflammation in atherosclerosis: From vascular biology to biomarker discovery and risk prediction
-
DOI 10.1373/clinchem.2007.097360
-
R.R. Packard P. Libby 2008 Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction Clin Chem 54 24 38 10.1373/clinchem.2007.097360 1:CAS:528:DC%2BD1cXmtFelsg%3D%3D 18160725 (Pubitemid 351182593)
-
(2008)
Clinical Chemistry
, vol.54
, Issue.1
, pp. 24-38
-
-
Packard, R.R.S.1
Libby, P.2
-
5
-
-
39549093148
-
General cardiovascular risk profile for use in primary care: The Framingham heart study
-
DOI 10.1161/CIRCULATIONAHA.107.699579
-
R.B. D'Agostino Sr R.S. Vasan M.J. Pencina, et al. 2008 General cardiovascular risk profile for use in primary care: the Framingham Heart Study Circulation 117 743 753 10.1161/CIRCULATIONAHA.107.699579 18212285 (Pubitemid 351640675)
-
(2008)
Circulation
, vol.117
, Issue.6
, pp. 743-753
-
-
D'Agostino Sr., R.B.1
Vasan, R.S.2
Pencina, M.J.3
Wolf, P.A.4
Cobain, M.5
Massaro, J.M.6
Kannel, W.B.7
-
6
-
-
33846996345
-
Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: The Reynolds Risk Score
-
DOI 10.1001/jama.297.6.611
-
P.M. Ridker J.E. Buring N. Rifai N.R. Cook 2007 Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score JAMA 297 611 619 10.1001/jama.297.6.611 1:CAS:528:DC%2BD2sXhslCqtLk%3D 17299196 (Pubitemid 46257283)
-
(2007)
Journal of the American Medical Association
, vol.297
, Issue.6
, pp. 611-619
-
-
Ridker, P.M.1
Buring, J.E.2
Rifai, N.3
Cook, N.R.4
-
7
-
-
57749210419
-
C-reactive protein and parental history improve global cardiovascular risk prediction: The Reynolds Risk Score for men
-
10.1161/CIRCULATIONAHA.108.814251 1:CAS:528:DC%2BD1cXhtlyks7bE 18997194
-
P.M. Ridker N.P. Paynter N. Rifai, et al. 2008 C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men Circulation 118 2243 2251 10.1161/CIRCULATIONAHA.108.814251 1:CAS:528:DC%2BD1cXhtlyks7bE 18997194
-
(2008)
Circulation
, vol.118
, pp. 2243-2251
-
-
Ridker, P.M.1
Paynter, N.P.2
Rifai, N.3
-
8
-
-
34147146476
-
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 Update
-
DOI 10.1161/CIRCULATIONAHA.107.181546
-
L. Mosca C.L. Banka E.J. Benjamin, et al. 2007 Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update Circulation 115 1481 1501 10.1161/CIRCULATIONAHA.107.181546 17309915 (Pubitemid 46648385)
-
(2007)
Circulation
, vol.115
, Issue.11
, pp. 1481-1501
-
-
Mosca, L.1
Banka, C.L.2
Benjamin, E.J.3
Berra, K.4
Bushnell, C.5
Dolor, R.J.6
Ganiats, T.G.7
Gomes, A.S.8
Gornik, H.L.9
Gracia, C.10
Gulati, M.11
Haan, C.K.12
Judelson, D.R.13
Keenan, N.14
Kelepouris, E.15
Michos, E.D.16
Newby, L.K.17
Oparil, S.18
Ouyang, P.19
Oz, M.C.20
Petitti, D.21
Pinn, V.W.22
Redberg, R.F.23
Scott, R.24
Sherif, K.25
Smith, S.C.26
Sopko, G.27
Steinhorn, R.H.28
Stone, N.J.29
Taubert, K.A.30
Todd, B.A.31
Urbina, E.32
Wenger, N.K.33
more..
-
9
-
-
33644868473
-
Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
-
DOI 10.1161/CIRCULATIONAHA.105.548206, PII 0000301720060214000009
-
D.M. Lloyd-Jones E.P. Leip M.G. Larson, et al. 2006 Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age Circulation 113 791 798 10.1161/CIRCULATIONAHA.105.548206 16461820 (Pubitemid 43754299)
-
(2006)
Circulation
, vol.113
, Issue.6
, pp. 791-798
-
-
Lloyd-Jones, D.M.1
Leip, E.P.2
Larson, M.G.3
D'Agostino, R.B.4
Beiser, A.5
Wilson, P.W.F.6
Wolf, P.A.7
Levy, D.8
-
10
-
-
37749027640
-
CD40/CD40L system and vascular disease
-
10.1007/s11739-007-0076-0 1:STN:280:DC%2BD1c3psVKkuw%3D%3D 18043876
-
F. Santilli S. Basili P. Ferroni G. Davì 2007 CD40/CD40L system and vascular disease Intern Emerg Med 2 256 268 10.1007/s11739-007-0076-0 1:STN:280:DC%2BD1c3psVKkuw%3D%3D 18043876
-
(2007)
Intern Emerg Med
, vol.2
, pp. 256-268
-
-
Santilli, F.1
Basili, S.2
Ferroni, P.3
Davì, G.4
-
11
-
-
56049105881
-
Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16
-
10.1007/s11239-007-0156-z 1:CAS:528:DC%2BD1cXhtlalsL3L 17917707
-
B.A. Olenchock S.D. Wiviott S.A. Murphy, et al. 2008 Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16 J Thromb Thrombolysis 26 79 84 10.1007/s11239-007- 0156-z 1:CAS:528:DC%2BD1cXhtlalsL3L 17917707
-
(2008)
J Thromb Thrombolysis
, vol.26
, pp. 79-84
-
-
Olenchock, B.A.1
Wiviott, S.D.2
Murphy, S.A.3
-
12
-
-
54349093968
-
Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study
-
10.1016/j.ahj.2008.06.041 1:CAS:528:DC%2BD1cXht12gtLvP 19061720
-
J.F. Keaney Jr I. Lipinska M.G. Larson, et al. 2008 Clinical correlates, heritability, and genetic linkage of circulating CD40 ligand in the Framingham Offspring Study Am Heart J 156 1003 1009 10.1016/j.ahj.2008.06.041 1:CAS:528:DC%2BD1cXht12gtLvP 19061720
-
(2008)
Am Heart J
, vol.156
, pp. 1003-1009
-
-
Keaney Jr, J.F.1
Lipinska, I.2
Larson, M.G.3
-
13
-
-
57649217441
-
Interleukin-18 and the risk of future cardiovascular disease among initially healthy women
-
10.1016/j.atherosclerosis.2008.04.015 1:CAS:528:DC%2BD1cXhsFajsbzJ 18514203
-
B.M. Everett S. Bansal N. Rifai, et al. 2009 Interleukin-18 and the risk of future cardiovascular disease among initially healthy women Atherosclerosis 202 282 288 10.1016/j.atherosclerosis.2008.04.015 1:CAS:528:DC%2BD1cXhsFajsbzJ 18514203
-
(2009)
Atherosclerosis
, vol.202
, pp. 282-288
-
-
Everett, B.M.1
Bansal, S.2
Rifai, N.3
-
14
-
-
56149115078
-
Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome
-
10.1097/HJR.0b013e3282f37a6e 18525381
-
C. Espinola-Klein H.J. Rupprecht C. Bickel, et al. 2008 Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome Eur J Cardiovasc Prev Rehabil 15 278 284 10.1097/HJR.0b013e3282f37a6e 18525381
-
(2008)
Eur J Cardiovasc Prev Rehabil
, vol.15
, pp. 278-284
-
-
Espinola-Klein, C.1
Rupprecht, H.J.2
Bickel, C.3
-
15
-
-
64749093076
-
Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: Synergistic effect of inflammation and hyperglycemia
-
10.2337/dc08-1710 19092166
-
M. Trøseid I. Seljeflot E.M. Hjerkinn H. Arnesen 2009 Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia Diabetes Care 32 486 492 10.2337/dc08-1710 19092166
-
(2009)
Diabetes Care
, vol.32
, pp. 486-492
-
-
Trøseid, M.1
Seljeflot, I.2
Hjerkinn, E.M.3
Arnesen, H.4
-
16
-
-
66349123572
-
Myeloperoxidase, modified lipoproteins, and atherogenesis
-
10.1194/jlr.R800086-JLR200 19091698
-
S.J. Nicholls S.L. Hazen 2009 Myeloperoxidase, modified lipoproteins, and atherogenesis J Lipid Res 50 Suppl S346 S351 10.1194/jlr.R800086-JLR200 19091698
-
(2009)
J Lipid Res
, vol.50
, Issue.SUPPL
-
-
Nicholls, S.J.1
Hazen, S.L.2
-
17
-
-
67449123456
-
HDL, lipid peroxidation, and atherosclerosis
-
10.1194/jlr.E900001-JLR200 1:CAS:528:DC%2BD1MXks1WisLY%3D 19141435
-
B. Shao J.W. Heinecke 2009 HDL, lipid peroxidation, and atherosclerosis J Lipid Res 50 599 601 10.1194/jlr.E900001-JLR200 1:CAS:528:DC%2BD1MXks1WisLY%3D 19141435
-
(2009)
J Lipid Res
, vol.50
, pp. 599-601
-
-
Shao, B.1
Heinecke, J.W.2
-
18
-
-
34347225913
-
Serum Myeloperoxidase Levels Are Associated With the Future Risk of Coronary Artery Disease in Apparently Healthy Individuals. The EPIC-Norfolk Prospective Population Study
-
DOI 10.1016/j.jacc.2007.03.033, PII S0735109707013460
-
M.C. Meuwese E.S. Stroes S.L. Hazen, et al. 2007 Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study J Am Coll Cardiol 50 159 165 10.1016/j.jacc.2007.03.033 1:CAS:528: DC%2BD2sXnsFymu7c%3D 17616301 (Pubitemid 47002189)
-
(2007)
Journal of the American College of Cardiology
, vol.50
, Issue.2
, pp. 159-165
-
-
Meuwese, M.C.1
Stroes, E.S.G.2
Hazen, S.L.3
Van Miert, J.N.4
Kuivenhoven, J.A.5
Schaub, R.G.6
Wareham, N.J.7
Luben, R.8
Kastelein, J.J.P.9
Khaw, K.-T.10
Boekholdt, S.M.11
-
19
-
-
43849102348
-
Myeloperoxidase: A new biomarker of inflammation in ischemic heart disease and acute coronary syndromes
-
DOI 10.1155/2008/135625
-
V. Loria I. Dato F. Graziani L.M. Biasucci 2008 Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes Mediators Inflamm 2008 135625 10.1155/2008/135625 18382609 (Pubitemid 351697086)
-
(2008)
Mediators of Inflammation
, vol.2008
, pp. 135625
-
-
Loria, V.1
Dato, I.2
Graziani, F.3
Biasucci, L.M.4
-
20
-
-
67650214712
-
Determination of myeloperoxidase in EDTA plasma: Comparison of an enzyme-linked immunosorbent assay with a chemiluminescent automated immunoassay
-
10.1016/j.cca.2009.05.009 1:CAS:528:DC%2BD1MXoslCqtr4%3D 19463803
-
S. Zelzer G. Khoschsorur M. Stettin, et al. 2009 Determination of myeloperoxidase in EDTA plasma: comparison of an enzyme-linked immunosorbent assay with a chemiluminescent automated immunoassay Clin Chim Acta 406 62 65 10.1016/j.cca.2009.05.009 1:CAS:528:DC%2BD1MXoslCqtr4%3D 19463803
-
(2009)
Clin Chim Acta
, vol.406
, pp. 62-65
-
-
Zelzer, S.1
Khoschsorur, G.2
Stettin, M.3
-
21
-
-
44849096170
-
Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations
-
DOI 10.1373/clinchem.2007.101568
-
J. Shih S.A. Datwyler S.C. Hsu, et al. 2008 Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations Clin Chem 54 1076 1079 10.1373/clinchem.2007.101568 1:CAS:528:DC%2BD1cXmvVarsLk%3D 18509013 (Pubitemid 351793416)
-
(2008)
Clinical Chemistry
, vol.54
, Issue.6
, pp. 1076-1079
-
-
Shih, J.1
Datwyler, S.A.2
Hsu, S.C.3
Matias, M.S.4
Pacenti, D.P.5
Lueders, C.6
Mueller, C.7
Danne, O.8
Mockel, M.9
-
22
-
-
51449084637
-
Flavonoids as substrates and inhibitors of myeloperoxidase: Molecular actions of aglycone and metabolites
-
10.1021/tx8000835 1:CAS:528:DC%2BD1cXosVejs7Y%3D 18620432
-
Y. Shiba T. Kinoshita H. Chuman, et al. 2008 Flavonoids as substrates and inhibitors of myeloperoxidase: molecular actions of aglycone and metabolites Chem Res Toxicol 21 1600 1609 10.1021/tx8000835 1:CAS:528:DC%2BD1cXosVejs7Y%3D 18620432
-
(2008)
Chem Res Toxicol
, vol.21
, pp. 1600-1609
-
-
Shiba, Y.1
Kinoshita, T.2
Chuman, H.3
-
23
-
-
34247142940
-
Use of BNP and CRP as biomarkers in assessing cardiovascular disease: Diagnosis versus risk
-
10.2174/157016107779317251 1:CAS:528:DC%2BD2sXitlamsLc%3D 17266610
-
V.M. Miller M.M. Redfield J.P. McConnell 2007 Use of BNP and CRP as biomarkers in assessing cardiovascular disease: diagnosis versus risk Curr Vasc Pharmacol 5 15 25 10.2174/157016107779317251 1:CAS:528:DC%2BD2sXitlamsLc%3D 17266610
-
(2007)
Curr Vasc Pharmacol
, vol.5
, pp. 15-25
-
-
Miller, V.M.1
Redfield, M.M.2
McConnell, J.P.3
-
24
-
-
41349087144
-
B-type natriuretic peptide (BNP) and proBNP: Role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders
-
10.1097/MJT.0b013e31815af96f 18356635
-
D. Godkar K. Bachu B. Dave, et al. 2008 B-type natriuretic peptide (BNP) and proBNP: role of emerging markers to guide therapy and determine prognosis in cardiovascular disorders Am J Ther 15 150 156 10.1097/MJT.0b013e31815af96f 18356635
-
(2008)
Am J Ther
, vol.15
, pp. 150-156
-
-
Godkar, D.1
Bachu, K.2
Dave, B.3
-
25
-
-
66349111768
-
B-type natriuretic peptide: A strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department
-
10.1097/MCA.0b013e3283292ac6 19293713
-
R. Bassan B.R. Tura A.S. Maisel 2009 B-type natriuretic peptide: a strong predictor of early and late mortality in patients with acute chest pain without ST-segment elevation in the emergency department Coron Artery Dis 20 143 149 10.1097/MCA.0b013e3283292ac6 19293713
-
(2009)
Coron Artery Dis
, vol.20
, pp. 143-149
-
-
Bassan, R.1
Tura, B.R.2
Maisel, A.S.3
-
26
-
-
66349102004
-
Incremental value of high-sensitivity C-reactive protein and N-terminal pro-Btype natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients
-
10.1097/MCA.0b013e3283219e47 19322079
-
D. Goei S.E. Hoeks E. Boersma, et al. 2009 Incremental value of high-sensitivity C-reactive protein and N-terminal pro-Btype natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients Coron Artery Dis 20 219 224 10.1097/MCA.0b013e3283219e47 19322079
-
(2009)
Coron Artery Dis
, vol.20
, pp. 219-224
-
-
Goei, D.1
Hoeks, S.E.2
Boersma, E.3
-
27
-
-
33947330983
-
Prognostic Value of B-Type Natriuretic Peptides in Patients With Stable Coronary Artery Disease. The PEACE Trial
-
DOI 10.1016/j.jacc.2007.03.038, PII S0735109707013538
-
T. Omland M.S. Sabatine K.A. Jablonski, et al. 2007 Prognostic value of B-type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial J Am Coll Cardiol 50 205 214 10.1016/j.jacc.2007.03.038 1:CAS:528:DC%2BD2sXnslGht7o%3D 17631211 (Pubitemid 47031568)
-
(2007)
Journal of the American College of Cardiology
, vol.50
, Issue.3
, pp. 205-214
-
-
Omland, T.1
Sabatine, M.S.2
Jablonski, K.A.3
Rice, M.M.4
Hsia, J.5
Wergeland, R.6
Landaas, S.7
Rouleau, J.L.8
Domanski, M.J.9
Hall, C.10
Pfeffer, M.A.11
Braunwald, E.12
-
28
-
-
33747079319
-
Comparative impact of multiple biomarkers and N-terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) study
-
DOI 10.1161/CIRCULATIONAHA.105.590927, PII 0000301720060718000007
-
S. Blankenberg M.J. McQueen M. Smieja, et al. 2006 Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study Circulation 114 201 208 10.1161/CIRCULATIONAHA.105.590927 1:CAS:528:DC%2BD28Xms1yrtLo%3D 16831981 (Pubitemid 44297113)
-
(2006)
Circulation
, vol.114
, Issue.3
, pp. 201-208
-
-
Blankenberg, S.1
McQueen, M.J.2
Smieja, M.3
Pogue, J.4
Balion, C.5
Lonn, E.6
Rupprecht, H.J.7
Bickel, C.8
Tiret, L.9
Cambien, F.10
Gerstein, H.11
Munzel, T.12
Yusuf, S.13
-
29
-
-
58549118043
-
Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: The epidemiological evidence
-
10.1007/s10557-008-6135-6 1:CAS:528:DC%2BD1MXotVyrug%3D%3D 18949547
-
W. Koenig N. Khuseyinova 2009 Lipoprotein-associated and secretory phospholipase A2 in cardiovascular disease: the epidemiological evidence Cardiovasc Drugs Ther 23 85 92 10.1007/s10557-008-6135-6 1:CAS:528: DC%2BD1MXotVyrug%3D%3D 18949547
-
(2009)
Cardiovasc Drugs Ther
, vol.23
, pp. 85-92
-
-
Koenig, W.1
Khuseyinova, N.2
-
30
-
-
51749105639
-
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker
-
10.1016/j.amjcard.2008.04.018 1:CAS:528:DC%2BD1cXosVantr8%3D 18549871
-
M.A. Corson P.H. Jones M.H. Davidson 2008 Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker Am J Cardiol 101 41F 50F 10.1016/j.amjcard.2008.04.018 1:CAS:528:DC%2BD1cXosVantr8%3D 18549871
-
(2008)
Am J Cardiol
, vol.101
-
-
Corson, M.A.1
Jones, P.H.2
Davidson, M.H.3
-
31
-
-
60249094866
-
Use of biomarkers to develop treatment strategies for atherosclerosis
-
18647586
-
M.A. Crandall M.A. Corson 2008 Use of biomarkers to develop treatment strategies for atherosclerosis Curr Treat Options Cardiovasc Med 10 304 315 18647586
-
(2008)
Curr Treat Options Cardiovasc Med
, vol.10
, pp. 304-315
-
-
Crandall, M.A.1
Corson, M.A.2
-
32
-
-
34249701265
-
Local production of lipoprotein-associated phospholipase A2 and lysophosphatidylcholine in the coronary circulation: Association with early coronary atherosclerosis and endothelial dysfunction in humans
-
DOI 10.1161/CIRCULATIONAHA.106.671420
-
2 and lysophosphatidylcholine in the coronary circulation: association with early coronary atherosclerosis and endothelial dysfunction in humans Circulation 115 2715 2721 10.1161/CIRCULATIONAHA.106.671420 1:CAS:528:DC%2BD2sXlsVOns7Y%3D 17502572 (Pubitemid 46842787)
-
(2007)
Circulation
, vol.115
, Issue.21
, pp. 2715-2721
-
-
Lavi, S.1
McConnell, J.P.2
Rihal, C.S.3
Prasad, A.4
Mathew, V.5
Lerman, L.O.6
Lerman, A.7
-
33
-
-
44449157784
-
Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques
-
10.1161/STROKEAHA.107.503193 1:CAS:528:DC%2BD1cXkvVeitr0%3D 18356547
-
D. Mannheim J. Herrmann D. Versari, et al. 2008 Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques Stroke 39 1448 1455 10.1161/STROKEAHA.107.503193 1:CAS:528: DC%2BD1cXkvVeitr0%3D 18356547
-
(2008)
Stroke
, vol.39
, pp. 1448-1455
-
-
Mannheim, D.1
Herrmann, J.2
Versari, D.3
-
34
-
-
60249101701
-
Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): A phase II double-blind, randomised, placebo-controlled trial
-
10.1016/S0140-6736(09)60403-7 1:CAS:528:DC%2BD1MXitFyrsLc%3D 19231633
-
R.S. Rosenson C. Hislop D. McConnell, et al. 2009 Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial Lancet 373 649 658 10.1016/S0140-6736(09)60403-7 1:CAS:528:DC%2BD1MXitFyrsLc%3D 19231633
-
(2009)
Lancet
, vol.373
, pp. 649-658
-
-
Rosenson, R.S.1
Hislop, C.2
McConnell, D.3
-
35
-
-
53549093853
-
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
-
10.1038/nm.1870 1:CAS:528:DC%2BD1cXht1Slu7rE 18806801
-
R.L. Wilensky Y. Shi E.R. Mohler 3rd, et al. 2008 Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development Nat Med 14 1059 1066 10.1038/nm.1870 1:CAS:528: DC%2BD1cXht1Slu7rE 18806801
-
(2008)
Nat Med
, vol.14
, pp. 1059-1066
-
-
Wilensky, R.L.1
Shi, Y.2
Mohler III, E.R.3
-
36
-
-
54049152760
-
Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque
-
10.1161/CIRCULATIONAHA.108.771899 1:CAS:528:DC%2BD1cXhtVOiurjK 18765397
-
P.W. Serruys H.M. García-García P. Buszman, et al. 2008 Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque Circulation 118 1172 1182 10.1161/CIRCULATIONAHA.108.771899 1:CAS:528:DC%2BD1cXhtVOiurjK 18765397
-
(2008)
Circulation
, vol.118
, pp. 1172-1182
-
-
Serruys, P.W.1
García-García, H.M.2
Buszman, P.3
-
37
-
-
49449096539
-
Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2
-
10.1021/jm800422v 1:CAS:528:DC%2BD1cXot1ahtbs%3D 18605714
-
R.C. Oslund N. Cermak M.H. Gelb 2008 Highly specific and broadly potent inhibitors of mammalian secreted phospholipases A2 J Med Chem 51 4708 4714 10.1021/jm800422v 1:CAS:528:DC%2BD1cXot1ahtbs%3D 18605714
-
(2008)
J Med Chem
, vol.51
, pp. 4708-4714
-
-
Oslund, R.C.1
Cermak, N.2
Gelb, M.H.3
-
38
-
-
44449119583
-
Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein
-
10.1074/jbc.M709970200 1:CAS:528:DC%2BD1cXisFOktrw%3D 18165686
-
B. Davis G. Koster L.J. Douet, et al. 2008 Electrospray ionization mass spectrometry identifies substrates and products of lipoprotein-associated phospholipase A2 in oxidized human low density lipoprotein J Biol Chem 283 6428 6437 10.1074/jbc.M709970200 1:CAS:528:DC%2BD1cXisFOktrw%3D 18165686
-
(2008)
J Biol Chem
, vol.283
, pp. 6428-6437
-
-
Davis, B.1
Koster, G.2
Douet, L.J.3
-
39
-
-
43449090390
-
Variability of lipoprotein-associated phospholipase A2 measurements
-
DOI 10.1373/clinchem.2008.103358
-
J.P. McConnell A.S. Jaffe 2008 Variability of lipoprotein-associated phospholipase A2 measurements Clin Chem 54 932 933 10.1373/clinchem.2008.103358 1:CAS:528:DC%2BD1cXlsVWju7k%3D 18443185 (Pubitemid 351671617)
-
(2008)
Clinical Chemistry
, vol.54
, Issue.5
, pp. 932-933
-
-
McConnell, J.P.1
Jaffe, A.S.2
-
40
-
-
55249087635
-
Genetically elevated C-reactive protein and ischemic vascular disease
-
10.1056/NEJMoa0707402 1:CAS:528:DC%2BD1cXhtlaitbbE 18971492
-
J. Zacho A. Tybjaerg-Hansen J.S. Jensen, et al. 2008 Genetically elevated C-reactive protein and ischemic vascular disease N Engl J Med 359 1897 1908 10.1056/NEJMoa0707402 1:CAS:528:DC%2BD1cXhtlaitbbE 18971492
-
(2008)
N Engl J Med
, vol.359
, pp. 1897-1908
-
-
Zacho, J.1
Tybjaerg-Hansen, A.2
Jensen, J.S.3
-
41
-
-
51649092992
-
C-reactive protein and coronary heart disease: A critical review
-
10.1111/j.1365-2796.2008.02015.x 1:CAS:528:DC%2BD1cXht1Omt7%2FJ 18823504
-
J.P. Casas T. Shah A.D. Hingorani, et al. 2008 C-reactive protein and coronary heart disease: a critical review J Intern Med 264 295 314 10.1111/j.1365-2796.2008.02015.x 1:CAS:528:DC%2BD1cXht1Omt7%2FJ 18823504
-
(2008)
J Intern Med
, vol.264
, pp. 295-314
-
-
Casas, J.P.1
Shah, T.2
Hingorani, A.D.3
-
42
-
-
59649124121
-
Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: The role of comorbidities and environmental factors
-
10.1373/clinchem.2008.112334 19095729
-
R. Rückerl A. Peters N. Khuseyinova, et al. 2009 Determinants of the acute-phase protein C-reactive protein in myocardial infarction survivors: the role of comorbidities and environmental factors Clin Chem 55 322 335 10.1373/clinchem.2008.112334 19095729
-
(2009)
Clin Chem
, vol.55
, pp. 322-335
-
-
Rückerl, R.1
Peters, A.2
Khuseyinova, N.3
-
43
-
-
59649099505
-
The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines
-
10.1373/clinchem.2008.109728 1:CAS:528:DC%2BD1MXhvVWksrc%3D 19095730
-
S. Mora K. Musunuru R.S. Blumenthal 2009 The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines Clin Chem 55 219 228 10.1373/clinchem.2008.109728 1:CAS:528:DC%2BD1MXhvVWksrc%3D 19095730
-
(2009)
Clin Chem
, vol.55
, pp. 219-228
-
-
Mora, S.1
Musunuru, K.2
Blumenthal, R.S.3
-
44
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL 18997196
-
P.M. Ridker E. Danielson F.A. Fonseca, et al. 2008 Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2195 2207 10.1056/NEJMoa0807646 1:CAS:528:DC%2BD1cXhtl2gurnL 18997196
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
45
-
-
63649095045
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
-
10.1016/S0140-6736(09)60447-5 1:CAS:528:DC%2BD1MXktV2gsL8%3D 19329177
-
P.M. Ridker E. Danielson F.A. Fonseca, et al. 2009 Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Lancet 373 1175 1182 10.1016/S0140-6736(09)60447-5 1:CAS:528:DC%2BD1MXktV2gsL8%3D 19329177
-
(2009)
Lancet
, vol.373
, pp. 1175-1182
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
-
46
-
-
61549111294
-
Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: Implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study
-
10.1016/j.jacc.2008.12.010 1:CAS:528:DC%2BD1MXjtFOjsLs%3D 19281922
-
E.D. Michos R.S. Blumenthal 2009 Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study J Am Coll Cardiol 53 931 935 10.1016/j.jacc.2008.12.010 1:CAS:528: DC%2BD1MXjtFOjsLs%3D 19281922
-
(2009)
J Am Coll Cardiol
, vol.53
, pp. 931-935
-
-
Michos, E.D.1
Blumenthal, R.S.2
|